Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Dasatinib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Burkitt Lymphoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Philadelphia Chromosome 1 Pancreatic Neoplasms 1 Neuroblastoma 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Brain Neoplasms 1 Blast Crisis 1

Interventions

Cyclophosphamide 12 Rituximab 11 obinutuzumab 9 fludarabine 9 Prednisone 7 ibrutinib 6 Lenalidomide 6 tocilizumab 5 fludarabine phosphate 5 Biopsy 5 venetoclax 4 pirtobrutinib 4 glofitamab 4 Specimen Handling 4 Doxorubicin 4 polatuzumab vedotin 3 X-Rays 3 Vincristine 3 Phantoms, Imaging 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 tucatinib 2 temsirolimus 2 pertuzumab 2 palbociclib 2 olaparib 2 cobimetinib 2 Whole-Body Irradiation 2 Vemurafenib 2 Trastuzumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03297606 2026-03-04

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡